Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has secured a definitive development and clinical manufacturing agreement valued at approximately $5.1 million in committed base service fees through its wholly owned subsidiary, Scinai Biopharma Services Ltd. The agreement, with a U.S.-based, Nasdaq-listed biopharmaceutical company, expands an existing customer relationship and covers development and clinical manufacturing services for an investigational oncology product. Revenue from the contract is expected during 2026 and 2027, with stability services extending beyond 2027. The full details of the announcement are available at https://ibn.fm/5jaNp.
The deal marks a significant acceleration in Scinai's CDMO business. Following the agreement, Scinai's committed customer orders across its Jerusalem and Yavne operations reached approximately $7.6 million, up 300% from $1.9 million at year-end 2025 and more than double the $3.1 million reported in August 2026. This sharp increase underscores the growing demand for Scinai's contract development and manufacturing services, particularly in the oncology space. The agreement also presents potential additional clinical manufacturing opportunities with an indicative, uncommitted value of $5.85 million for late 2027 through the first half of 2028, subject to further agreements and development milestones. Investors can find more news and updates on Scinai at https://ibn.fm/SCNI.
Scinai Immunotherapeutics operates a dual-pronged strategy: advancing a pipeline of innovative immunology therapies and providing CDMO services to biotechnology and pharmaceutical companies. The company's therapeutic candidates are licensed from the Max Planck Society and PinCell S.r.l., while its CDMO operations serve clients from facilities in Jerusalem and Yavne, Israel. For a deeper look at the company, visit Scinai Immunotherapeutics (NASDAQ: SCNI).
The new agreement is important because it demonstrates Scinai's ability to convert existing customer relationships into larger, multi-year contracts, providing revenue visibility and validating its manufacturing capabilities. The 300% increase in committed orders since year-end 2025 signals strong commercial momentum and could position the company for further growth as it pursues additional opportunities. The potential $5.85 million in uncommitted work suggests a pipeline of future business that, if realized, would extend the company's revenue trajectory well into 2028.
MissionIR, a specialized communications platform, published the news break. MissionIR is part of the Dynamic Brand Portfolio within IBN, which offers a range of services including wire distribution through InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution. For more information about MissionIR and its services, visit MissionIR.
